Key Takeaways:
- PathoQuest is a Paris-based startup focusing on improving pathogen detection through using a metagenomics approach.
- This next-generation sequencing (NGS) based testing approach offers exhaustive identification of pathogens, overcoming limitations on infectious agent detection.
- The company’s first commercial application, the Viral Safety testing service for biopharmaceutical companies, has quickly established a consistent revenue stream.
What if detecting pathogens could be as meticulous and exhaustive as browsing through a comprehensive library? Biotechnology is moving closer to achieving this feat thanks to Paris-based startup PathoQuest. The company is harnessing next-generation sequencing (NGS) technology, ushering a revolutionary approach in pathogen detection that promises to shake up European healthcare industry.
PathoQuest is a spin-off company from the renowned Institut Pasteur. By using a comprehensive database of pathogens’ genomic information, PathoQuest’s proprietary testing approach offers clinicians, biologists, and biopharmaceutical managers an efficient tool for diagnosis, research, and quality assurance, going beyond traditional limitations on infectious agent detection.
What sets PathoQuest apart from traditional diagnostic methods is its superior breadth and depth in identifying pathogens. Their proprietary technology goes beyond just generic detection to identifying the exact strain of pathogens, including bacteria, viruses, fungi, and parasites. By deploying metagenomics approach in pathogen detection, it also surmounts the limitations of traditional culture-based and molecular diagnostic tests that only target specific microorganisms.
Another aspect that sets PathoQuest apart is its strong connection to the biopharmaceutical industry. The company’s first commercial application, Viral Safety testing service, is a much-needed solution for biopharmaceutical quality assurance managers/production managers. This not only addresses a significant need in the industry but also represents a dependable revenue stream for PathoQuest.
With the demand for reliable pathogen detection becoming increasingly critical, the future of PathoQuest and the biotechnology industry appears promising. As more healthcare providers and biopharmaceutical companies grasp the tangible benefits of NGS-based metagenomic tests, PathoQuest could potentially revolutionize pathogen detection and diagnosis in the European healthcare industry.
PathoQuest’s forward-thinking approach holds suitably high promise in not only identifying infectious agents but also future-proofing public health efforts, particularly in times when pandemics could be an unfortunate part of the new normal. For more information on PathoQuest’s advancements, make sure to visit their website, follow them on Twitter, or connect with them on LinkedIn.
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
